Sharon Morriss

Dr. Sharon Morriss joined Lung Therapeutics in June 2021 as the SVP, Clinical Development. Dr. Morriss has more than fifteen years of experience leading clinical development teams from pre-clinical through to Commercialization for biotechnology companies.

In her most recent position, she served as SVP, Clinical Development Operations at Apellis Pharmaceuticals, where her numerous responsibilities included the advancement of the company's rare disease and ophthalmology clinical portfolio. This led to the FDA approval of EMPAVELlä (pegcetacoplan), targeted C3 therapy for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). Dr. Morriss built and led the global clinical development operations team, creating a team to advance the diverse clinical platform through registrational clinical studies in hematology, nephrology, neurology, and ophthalmology. Dr. Morriss also chaired the Joint Development Committee for Apellis' global co-development alliance for systemic pegcetacoplan with Swedish Orphan Biovitrum (Sobiä).